Surreal illustration of pills forming a sample size bell curve with DNA strands, symbolizing bioequivalence in pharmaceutical research.

Decoding Bioequivalence: How Sample Size Impacts Generic Drug Studies

Avery Sinclair monogram
Avery Sinclair in Health & Wellness October 2026 • 5 min read.

"Navigating the complexities of generic drug approval: Understanding intra-subject variation and sample size optimization for reliable bioequivalence studies."


When a pharmaceutical company wants to release a generic version of a brand-name drug, it needs to prove to regulatory agencies that its version is bioequivalent, meaning it performs in the same way in the human body. Bioequivalence studies are performed using a crossover design, information on the intra-subject coefficient of variation (intra-CV) for pharmacokinetic measures is needed when determining the sample size. One of the most important aspects of these studies is determining the appropriate sample size. This ensures that the study has enough statistical power to detect any real differences between the generic and brand-name drugs.

The intra-subject coefficient of variation (intra-CV) plays a vital role in the determination of sample size. The intra-CV reflects the variability within a single subject's response to a drug. This variability can arise from various factors, including differences in metabolism, absorption, and elimination. Therefore, accurately estimating intra-CV is crucial for calculating the appropriate sample size.

According to a study published in Translational Clinical Pharmacology, calculated intra-CVs based on bioequivalence results of identical generic drugs produce different estimates. To address this challenge, researchers analyzed data from numerous bioequivalence studies to better understand the variability of intra-CVs and their impact on sample size calculations. The data was collected from public resources from the Ministry of Food and Drug Safety (MFDS) and calculated the intra-CVs of various generics.

AI Search Multiple angles on this topic

Bioequivalence Methods and Regulatory Review

Bioequivalence studies provide a scientific and regulatory basis for generic drug approval by supporting a finding of therapeutic equivalence to an innovator product without repeating full clinical efficacy testing, according to the review on study design and regulatory requirements. The FDA’s August 18, 2022 guidance addresses biopharmaceutical classification of drug substances and BCS-based biowaivers of bioequivalence studies. A 2025 review describes bioequivalence studies as a way to ensure generic formulations meet safety and efficacy standards established by innovator products. These sources describe established assessment and waiver approaches, but the supplied summaries do not specify their limitations in detail.

From FDA Rules to Generic Reference Products

FDA bioequivalence regulations began in 1977, and evaluation later evolved to include the two one-sided test procedure, according to the 2014 history chapter. The history review also points to Westlake’s 1972 work on using confidence intervals to analyze comparative bioavailability. For generic medicines, the 2009 review describes in vivo equivalence, or bioequivalence, studies as a means of establishing interchangeability with innovator products. The 2026 history article explains that an abbreviated new drug application identifies the originator’s product and strength—the Reference Listed Drug—to use in generic studies.

Why Sample Size Matters in Bioequivalence Studies

Surreal illustration of pills forming a sample size bell curve with DNA strands, symbolizing bioequivalence in pharmaceutical research.

Statistically, power represents the probability the null hypothesis will be rejected when the alternative hypothesis is true. In bioequivalence studies, the null hypothesis posits that the substances are bioinequivalent. Therefore, the power of a bioequivalence study is the probability of proving bioequivalence when the products are in fact bioequivalent. Because finding the optimal sample size ensures adequate power, the sample size calculation is one of the most important steps in designing a bioequivalence study.

Choosing the right sample size is a balancing act. A sample size that is too large can unnecessarily increase the cost of the study and expose an excessive number of participants to the drug. On the other hand, a sample size that is too small increases the risk of a type II error, which means failing to detect a real difference between the drugs. This can result in the rejection of a bioequivalent generic drug.

  • Regulatory Guidelines: According to statistical guidelines from the U.S. FDA and EMA, a power of 80% or 90% is generally recommended for bioequivalence studies.
  • Impact of Intra-CV: Determining the sample size requires considering the intra-subject coefficient of variation (intra-CV) of pharmacokinetic measures. However, intra-CVs can vary considerably among studies of identical generics.
  • Variability in Practice: For example, the reported intra-CVs of metformin's maximum concentration (Cmax) were 12.1% and 24.8% in two different bioequivalence studies. This highlights that relying on a single bioequivalence result may not provide sufficient power for planning a trial.
AI Search Multiple angles on this topic

Study Designs, Variability, and Virtual Trials

A South Korean analysis examined 588 bioequivalence studies involving 143 generic drugs from 2013 through 2019. A separate analysis compiled clinical bioequivalence parameters for 278 oral formulations representing 238 compounds, including highest-dose tablets, orally disintegrating tablets, and capsules. An open-source framework paper focuses on virtual bioequivalence modeling and clinical-trial design, describing the goal as demonstrating a comparable rate and extent of active ingredient reaching the site of action. These works address study-report patterns, formulation variability, and modeling, respectively.

Minimum Sample Sizes May Be Insufficient

A post hoc analysis examined intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies. In 44 of the 58 generics evaluated, the estimated optimal sample size was larger than the MFDS-requested minimum of 12 participants. This finding suggests that the minimum did not match the calculated optimal size for many of the generics in that analysis. The supplied summary does not provide the individual optimal sample sizes.

A Six-Volunteer Cinitapride Comparison

A study of cinitapride in healthy human volunteers assessed the bioavailability of test product A in comparison with reference product B. The study objective specified six normal, adult human subjects under fasting conditions. This provides a concrete example of a small-sample comparative bioavailability study. The supplied summary does not report the study’s results or explain how its sample size was selected.

The Ministry of Food and Drug Safety (MFDS) of Korea has been releasing bioequivalence study results to the public since January 2014. These data include information for power and sample size calculations in bioequivalence studies, such as 90% confidence intervals for the area under the concentration-time curve (AUC) and Cmax, as well as sample sizes. However, these data also demonstrate considerable variability in sample sizes for bioequivalence studies on the same generic drugs.

Implications for Future Research

The insights from this study emphasize the importance of carefully considering intra-subject variability when designing bioequivalence studies. By using pooled intra-CVs from multiple studies, researchers can obtain more reliable estimates for sample size calculations, ultimately leading to more robust and conclusive results. These findings can help ensure that generic drugs are properly evaluated and that patients have access to safe and effective medications.

AI Search Multiple angles on this topic

FDA Perspective on Generic Bioequivalence

The FDA material is titled “Introduction of Bioequivalence for Generic Drug Products” and identifies Ja Hye Myung, Ph.D., as its presenter. The listed role is pharmacologist in the Division of Bioequivalence III, Office of Bioequivalence, Office of Generic Drugs, CDER, at the U.S. FDA. The supplied source information establishes the presentation’s subject and institutional perspective but does not include its substantive recommendations or conclusions.

Model-Integrated Bioequivalence

Model-Integrated Bioequivalence (MIBE) is described as an emerging approach in generic drug development. The source says it has the potential to reduce reliance on unnecessary clinical bioequivalence studies, improve development efficiency, and minimize subject burden, particularly for complex drug products. These are stated as potential benefits, rather than reported outcomes of a specific quantified comparison. The supplied summary does not give adoption figures or a timeline.

Costs, Timelines, and Population Representation

A 2025 perspective identifies substantial costs, lengthy timelines, and narrow population representation as constraints of current bioequivalence assessment methods for generic drugs. It examines whether integrating computational methods with in vitro–in vivo correlation (IVIVC) and real-world evidence (RWE) might address these challenges. The source frames this integration as a possibility, particularly for transitional regulatory settings. The supplied summary does not quantify the costs or describe demonstrated effects on representation.

How variability translated into sample-size estimates

  • 30%For generics whose estimated intra-CV of AUC and/or Cmax exceeded 30%, the estimated sample size averaged 58.3 participants, compared with 16.8 for generics below that variability threshold.[1]

Reading the variability findings

The estimates show why a single sample-size assumption may not fit every generic: higher estimated intra-subject variability corresponded to larger calculated samples in this analysis.[1]

Limits of the sample-size analysis

  • The reference-drug variability estimates were limited to studies using a two-period, two-sequence crossover design.[1]
  • The study derived estimates from publicly available Korean bioequivalence results, which bounds the analysis to those reported studies and data.[1]
Study at a glance
Sample size142 bioequivalence study results from 58 generics[2]
Main outcomeIntra-CVs of AUC and Cmax and optimal sample sizes for bioequivalence studies[2]
Confidence intervalPooled CV and its upper 80% confidence limit for 26 generics with multiple bioequivalence results[2]
FundingGrant no. 12-2013-026 from the SNUBH Research Fund[2]
Times cited12[2]

Sources

  1. A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies (Europe PMC, 2018)
  2. A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies (Korean Society for Clinical Pharmacology and Therapeutics, 2018)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.12793/tcp.2018.26.1.6, Alternate LINK

Title: A Post Hoc Analysis Of Intra-Subject Coefficients Of Variation In Pharmacokinetic Measures To Calculate Optimal Sample Sizes For Bioequivalence Studies

Subject: Pharmacology (medical)

Journal: Translational and Clinical Pharmacology

Publisher: Korean Society for Clinical Pharmacology and Therapeutics

Authors: Inbum Chung, Jaeseong Oh, Seunghwan Lee, In-Jin Jang, Youngjo Lee, Jae-Yong Chung

Published: 2018-01-01

Everything You Need To Know

1

Why is determining the right sample size so critical in bioequivalence studies?

In bioequivalence studies, sample size is crucial because it directly impacts the study's statistical power. Adequate power ensures that if the generic and brand-name drugs are indeed bioequivalent, the study is likely to demonstrate this. An insufficient sample size increases the risk of failing to detect the bioequivalence, potentially leading to the rejection of a safe and effective generic drug. Conversely, an excessively large sample size can unnecessarily increase costs and expose more participants to the drug. Therefore, optimizing sample size is a balancing act to achieve reliable and ethical study outcomes.

2

What is the 'intra-subject coefficient of variation (intra-CV),' and why is it so important when designing bioequivalence studies?

The intra-subject coefficient of variation (intra-CV) reflects the variability in how a single person responds to a drug over time. This variability arises from differences in metabolism, absorption, and elimination processes within an individual. Accurately estimating the intra-CV is crucial because it directly influences the sample size calculation in bioequivalence studies. Higher intra-CV values indicate greater variability, necessitating larger sample sizes to achieve adequate statistical power. Failing to account for intra-subject variability can lead to underpowered studies and unreliable conclusions about bioequivalence.

3

What power do regulatory guidelines from the U.S. FDA and EMA generally recommend for bioequivalence studies, and what does this mean?

Regulatory bodies like the U.S. FDA and EMA provide statistical guidelines recommending a power of 80% or 90% for bioequivalence studies. This means that there should be an 80% or 90% chance of correctly concluding bioequivalence if the generic and brand-name drugs are truly equivalent. These guidelines ensure that bioequivalence studies have sufficient statistical rigor to protect public health by ensuring that generic drugs are as safe and effective as their brand-name counterparts. Adhering to these guidelines is essential for obtaining regulatory approval for generic drugs.

4

What kind of bioequivalence study data does the Ministry of Food and Drug Safety (MFDS) of Korea release, and how can this information be useful?

The Ministry of Food and Drug Safety (MFDS) in Korea releases data from bioequivalence studies, including information on 90% confidence intervals for AUC (area under the concentration-time curve) and Cmax (maximum concentration), as well as sample sizes. These data are valuable because they provide researchers with real-world examples of variability in bioequivalence studies. Analyzing this data helps researchers better understand the range of intra-CVs and their impact on sample size calculations. However, the data also reveal considerable variability in sample sizes for studies on the same generic drugs, emphasizing the need for careful consideration of intra-subject variability.

5

How can using pooled intra-CVs from multiple studies improve the reliability of bioequivalence studies, and what are the implications of this approach?

Using pooled intra-CVs from multiple bioequivalence studies leads to more reliable estimates for sample size calculations. Single-study intra-CVs can be highly variable, potentially resulting in underpowered or overpowered studies. By pooling data from multiple studies, researchers can obtain a more stable and representative estimate of intra-subject variability. This approach enhances the robustness and conclusiveness of bioequivalence studies, ultimately contributing to the assurance that generic drugs are properly evaluated and that patients receive safe and effective medications. This approach acknowledges the inherent uncertainties and variations in drug responses, providing a more evidence-based foundation for regulatory decisions and clinical practice.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.